Notably, co-expression of AR and FOXA1 was observed by immunohistochemistry (IHC) in ~15% of triple-negative breast cancer (TNBC) patients24, and AR-positive (AR+), FOXA1-positive (FOXA1+) patients had a significant decrease in recurrence-free survival and overall survival compared to TNBC patients25. This evidence concerns the gene AR and triple-negative breast carcinoma.